With a median follow-up of 25.6 months as of a data cutoff of Jan. 30, 2024, the median progression-free survival was 14.6 months in the Lenvima plus Keytruda arm, with 132 progression-free survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback